Investigational drug · Phase 3
Inactive control
Also called: QLS-111 vehicle
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hepatocellular Carcinoma, Cirrhosis, Open-angle Glaucoma (OAG).
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 29, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
563
Any phase or sponsor naming "Inactive control"
First trial start
2023
Mar 15, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Inactive control", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma
- Cirrhosis
- Open-angle Glaucoma (OAG)
- Ocular Hypertension (OHT)
- Glaucoma
Approved drugs for the same conditions: High blood pressure (hypertension) · Liver cancer (hepatocellular carcinoma) · Glaucoma · Oncology · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "Inactive control" as an intervention, largest first.
- Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster StudyPivotal-lookingCompleted
Livzon Pharmaceutical Group Inc.Industry
NCT05096832 · 10,381 participants · Start Nov 3, 2021 · Primary completion Feb 18, 2022
Drug: Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01); Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) · For: COVID-19 Pandemic
Sites: Kuching, Malaysia; Kuala Lumpur, Malaysia; Muar town, Malaysia · 18 sites in all
- Testing and Linkage to Care for Injecting Drug Users in KenyaPivotal-lookingCompleted
Yale UniversityAcademic, hospital or other
NCT01557998 · 9,449 participants · Start May 2012 · Primary completion Apr 30, 2016
Drug: HCV+PWID · For: HIV Infection; HCV Coinfection
Sites: Nairobi, Kenya
- EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)Pivotal-lookingActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06531824 · 8,371 participants · Start Aug 30, 2024 · Primary completion Dec 31, 2026
Drug: BI 690517; Placebo matching BI 690517 and 1 more · For: Kidney Disease, Chronic
Sites: Huntsville, Alabama; Surprise, Arizona; Beverly Hills, California · 562 sites in all
- A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes MellitusPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01989754 · 5,813 participants · Start Jan 16, 2014 · Primary completion Feb 23, 2017
Drug: Placebo; Canagliflozin, 100 mg and 1 more · For: Diabetes Mellitus, Type 2; Albuminuria
Sites: Little Rock, Arkansas; Carmichael, California; Concord, California · 341 sites in all
- CANVAS - CANagliflozin cardioVascular Assessment StudyPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01032629 · 4,330 participants · Start Dec 9, 2009 · Primary completion Feb 22, 2017
Drug: Placebo; Canagliflozin (JNJ-28431754) 100 mg and 1 more · For: Diabetes Mellitus, Type 2; Cardiovascular Diseases; Risk Factors
Sites: Birmingham, Alabama; Mesa, Arizona; Tucson, Arizona · 305 sites in all
- Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness PatientsPivotal-lookingStatus unknown
The University of Hong KongAcademic, hospital or other
NCT04143451 · 4,000 participants (planned) · Start Oct 23, 2019 · Primary completion Sep 30, 2022
Drug: Vaxigrip tetra; Fluzone high-dose and 2 more · For: Influenza
Sites: Hong Kong, Hong Kong
- Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute SinusitisPivotal-lookingRecruiting
Daniel MerensteinAcademic, hospital or other
NCT06076304 · 3,720 participants (planned) · Start Nov 21, 2023 · Primary completion Oct 2028
Drug: amoxicillin/clavulanate potassium; Placebo and 1 more · For: Sinus Infection; Acute Sinusitis
Sites: Los Angeles, California; Washington D.C., District of Columbia; Hyattsville, Maryland · 7 sites in all
- Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary BypassPivotal-lookingRecruiting
Xijing HospitalAcademic, hospital or other
NCT06702553 · 3,650 participants (planned) · Start May 19, 2025 · Primary completion Mar 31, 2028
Drug: Nitric Oxide Gas; Standard Care Arm · For: Nitric Oxide; Cardiac Surgery; Cardiopulmonary Bypass and 1 more
Sites: Boston, Massachusetts; Xi'an, China; Tomsk, Russia
- Secondary Prevention of Small Subcortical Strokes TrialPivotal-lookingCompleted
University of British ColumbiaAcademic, hospital or other
NCT00059306 · 3,020 participants · Start Feb 2003 · Primary completion Apr 2012
Drug: aspirin; clopidogrel · For: Cerebrovascular Accident; Hypertension
Sites: Mobile, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 63 sites in all
- Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke RiskPivotal-lookingTerminated
Biotronik, Inc.Industry
NCT00559988 · 2,718 participants · Start Feb 2008 · Primary completion Jun 2013
Drug: Home Monitoring Guided OAC; Physician-Directed OAC · For: Atrial Fibrillation; Atrial Flutter; Stroke and 2 more
Sites: Phoenix, Arizona; Scottsdale, Arizona; Anaheim, California · 80 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Transcranial alternating current stimulation for major depressive disorder: An updated systematic review and meta-analysis of randomized trials with GRADE assessment.
Nabil Y, Moghib KA, Tarek Z, et al. · J Affect Disord 2027
- Representation of racial and ethnic minorities in U.S. depression trials comparing psychotherapy vs. controls: A meta-analysis using state population benchmarks.
Segre L, Tong L, Kaya Aglio E, et al. · J Affect Disord 2026
- A pragmatic randomized controlled trial of self-directed online writing interventions for posttraumatic stress symptoms in a real-world digital setting.
Li M, Bao J, Ni T, et al. · Eur J Psychotraumatol 2026
- Efficacy of health behaviour interventions using the health action process approach: a systematic review and meta-analysis.
Xu M, Cai Z, Schwarzer R, et al. · Health Psychol Rev 2026
- A Systematic Review and Network Meta-Analysis of the Effectiveness of Psychological and Psychosocial Interventions for Reducing Posttraumatic Stress, Anxiety, or Depression Among Immigrant and Refugee Children and Youth.
Rafieifar M, Kirsch J, Adeleke C, et al. · Trauma Violence Abuse 2026
- Resistance Exercise Training for Depressive Symptoms: A Meta-Analysis and Meta-Regression Analysis.
O'Sullivan D, Rice JM, Meyer JD, et al. · JAMA Netw Open 2026
Also in development for Hepatocellular Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.